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Scavenger receptors act as membrane-bound and soluble proteins that bind to macromolecular complexes and pathogens. This
diverse supergroup of proteins mediates binding to modiﬁed lipoprotein particles which regulate the initiation and progression
of atherosclerotic plaques. In vascular tissues, scavenger receptors are implicated in regulating intracellular signaling, lipid
accumulation, foam cell development, and cellular apoptosis or necrosis linked to the pathophysiology of atherosclerosis. One
approach is using gene therapy to modulate scavenger receptor function in atherosclerosis. Ectopic expression of membrane-
bound scavenger receptors using viral vectors can modify lipid proﬁles and reduce the incidence of atherosclerosis. Alternatively,
expression of soluble scavenger receptors can also block plaque initiation and progression. Inhibition of scavenger receptor
expressionusingacombinedgenetherapyandRNAinterferencestrategyalsoholdspromiseforlong-termtherapy.Herewereview
our current understanding of the gene delivery by viral vectors to cells and tissues in gene therapy strategies and its application to
the modulation of scavenger receptor function in atherosclerosis.
1.Introduction
Scavenger receptors comprise a structurally diverse group
of proteins [1]. Originally identiﬁed by Brown and Gold-
stein, they were deﬁned by their ability to bind modiﬁed
forms of low density lipoprotein (LDL) including acetylated
LDL (AcLDL) and oxidized LDL (OxLDL) and were thus
implicated as key regulators in initiation and progression
of atherosclerosis [2]. This family of proteins has expanded
to include eight diﬀerent classes of membrane and soluble
proteins (Class A, B, C, D, E, F, G, and H) encoded by
distinct and unrelated genes [3]. Scavenger receptor classes
are grouped by the presence of shared structural domains;
however there is great structural diversity between the
diﬀerent classes. Despite this lack of sequence similarity or
identity, all scavenger receptors retain the capacity to bind
modiﬁed lipid particles in addition to a diverse range of
polyanionic ligands of host-derived orexogenous origins, for
example, pathogens [4, 5].
2. Genetics of Scavenger Receptors
Class A scavenger receptors comprise at least four related
genes: scavenger receptor A (SR-A), macrophage receptor
with collagenous structure (MARCO), scavenger receptor
with C-type lectin (SRCL), and scavenger receptor A-5
(SCARA5) [6–10]. The human and murine SR-A genes
are located on chromosome 8 and can be transcribed to
produce three (SR-AI/II/III) or two SR-A splice variants,
respectively [11]. SR-AI/II is largely found on macrophages2 International Journal of Hypertension
but are also present on endothelial cells and vascular smooth
musclecells(VSMCs).Oxidativestress,OxLDL,macrophage
colony-stimulating factor (M-CSF), and phorbol esters can
elevate SR-A levels [12–15]. SR-A is postulated to be
proatherogenicduetoitsabilitytomediateuptakeofOxLDL
in macrophages [16, 17]. Deﬁciency of SR-AI and SR-AII
not only led to the formation of smaller atherosclerotic
lesions, but also to a reduction of macrophage adhesion
and increased susceptibility to bacteria and viruses [18, 19].
MARCO is located on human chromosome 2 or mouse
chromosome 1 [20], and the gene product is expressed
largely on macrophages and on splenic dendritic cells to
al o w e re x t e n t[ 9, 21]. MARCO is implicated in host
defense and pathogen clearance since binding to dead or
apoptotic cells, bacteria, and lipopolysaccharides elevates
MARCO levels [22, 23]. When challenged with Streptococcus
pneumoniae,wildtypemicecouldcleartheinfectionwhereas
the ability was impaired in MARCO
−/− mice, demonstrating
the role of MARCO in the innate immune response against
pathogens [24]. MARCO expression in human alveolar
macrophages also plays a crucial role in the innate immunity
against bacteria [25]. Human and murine SRCL genes are
both located on chromosome 18 and can generate at least
2 splice variants in humans. In contrast to the other Class A
gene products, SRCL is detected on endothelial cells but not
macrophages[26]andmaybeinvolvedintheinnateimmune
response against fungal infections [27]. SCARA5 is located
on mouse chromosome 14: the resulting gene product is
detected on epithelial cells but not macrophages [7]a n d
may play unique role(s) in the innate immune system and
atherosclerosis [28].
Class B contains at least four members: CD36, SR-B (also
known as CLA-1 in humans), LIMPII-related genes, and
CD163.CD36 islocatedonhumanchromosome7ormurine
chromosome 5 [29] and its expression is mostly limited
to cells of lymphoid and hematopoietic lineages including
leukocytes, platelets, endothelial cells, adipocytes, VSMCs,
andsomeepithelialcells;itslevelsarehighestinmacrophages
[30, 31]. Double knockout SR-A
−/−/CD36
−/− mice show
increased foam cell formation and atherosclerotic lesion size,
suggesting that CD36 acts as a major cellular receptor for





no change in atherosclerotic lesion size but decreased levels
of various inﬂammatory gene products; ∼30% decrease
in macrophage apoptosis and ∼50% decrease in plaque
necrosis suggested delayed progression towards advanced,
unstable atherosclerotic lesions [34]. In the nematode C.
elegans, the CD36 orthologue (C03F11.3) mediates host
defense against fungal pathogens [35]. Higher levels of a
soluble form of CD36 are biomarkers of insulin resistance
and plaque instability in patients with diabetes and internal
carotid stenoses, respectively [36, 37]. CD36-deﬁcient mice
when challenged with pathogens were signiﬁcantly more
susceptible to the infections [38, 39]. Humans expressing
CD36 allelic variants were also more susceptible to malaria
[40]demonstratingitsimportantroleintheimmunesystem.
SR-BI (SCARB1) is located on human chromosome 12 or
mousechromosome5[41]andencodestwoproteinisoforms
(SR-BI/II) [42] in monocytes, macrophages, hepatocytes,
and adipose and steroidogenic tissues [43]. SR-BI expression
is elevated by either PPARα,P P A R γ, testosterone, PUFA, or
TSA [44–47] and downregulated by either OxLDL, TNF-α,
IL-1, or lipopolysaccharides [48, 49]. SR-B1 is a receptor for
hepatitis C virus, Plasmodium, and mycobacteria pathogens
[50–52]. In contrast to other scavenger receptors, SR-BI
could provide protective function(s) against atherosclerosis
by increasing the macrophage-based cholesterol eﬄux into
HDL particles followed by liver HDL clearance and excretion
[47, 53–56]. LIMPII is located on human chromosome 4
or mouse chromosome 5 and has a similar expression
proﬁle to SR-BI [31]. CD163 (M130) [57]i sl o c a t e di n
human chromosome 12 [58] and expressed in monocytes
and macrophages in both membrane-bound and soluble
forms [59] where it plays an important role in the regulation
of anti-inﬂammatory responses, pathogen recognition, and
atheroprotectionprobablythroughelevationinexpressionof
heme oxygenase and in removing free hemoglobin [60–63].
Patients with hematological, inﬂammatory, and lysosomal
storage diseases have also a high level of soluble CD163,
and it may thus serve as a biomarker for such conditions
[64, 65].
Class C comprises of just one scavenger receptor, dSR-
C1 which has only been so far identiﬁed in the fruit
ﬂy Drosophila melanogaster. dSR-C1 is a pattern recog-
nition receptor for bacteria expressed in hemocytes and
macrophages during ﬂy embryonic development [66]. It can
recognize bacteria and may play a role in the innate immune
system of the insect [67].
Class D comprises the CD68 and lysosomal membrane
glycoprotein (Lamp) gene products. CD68 is located on
human chromosome 17 and the murine orthologue (also
called macrosialin) is located on murine chromosome 11
[68]. Macrophages, Langerhans cells, dendritic cells, and
osteoclasts express CD68 in pattern similar to the class B
gene products [69]. The expression levels can be elevated
by OxLDL, GM-CSF, and phorbol ester but inhibited by
TNF-α and lipopolysaccharides [70–72]. Macrosialin levels
are also observed to be increased by a proatherogenic diet:
OxLDL and macrosialin were both found in macrophages
within atherosclerotic plaques from ApoE-deﬁcient mice
[73].MacrosialinhasbeenidentiﬁedasareceptorforOxLDL
[74–76] although this view has been challenged [77]. The
three Lamp genes (1, 2, and 3) are located in human
chromosome 13, X, and 3 or murine chromosomes 8, X,
and 16, respectively [78]. Lamp-1 and -2 are constitutively
and widely expressed whereas Lamp-3 is elevated during
dendritic cell maturation implying a functional link to the
immune system [79].
Class E comprises of just one member: the lectin-
like oxidized low density lipoprotein receptor 1 (LOX-1).
LOX-1 (OLR1) is located on human chromosome 12 [80]
or mouse chromosome 6 and is expressed on endothelial
cells, macrophages, smooth muscle cells, and platelets [81,
82]. The resting levels are relatively low but elevated by
proinﬂammatory stimuli including OxLDL, inﬂammatory
cytokines, for example, TNF-α, shear stress, oxidative stress,
phorbol ester, endothelin-1, and angiotensin II [83–87].International Journal of Hypertension 3
A splice variant (LOXIN) conferred protection against
the proatherogenic LOX-1 eﬀects by forming inactive
heterodimers with LOX-1 and blocking OxLDL-induced
apoptosis in macrophages [88, 89]. A human LOX-1 allelic
polymorphism (K167N) is postulated to increase the risk
of CVD in a patient cohort [90]. However, further inves-
tigations into the associations between the LOX-1-K167N
polymorphism, myocardial infarction (MI) and cardiovas-
cular disease (CVD) have produced conﬂicting data [91, 92]
suggesting that this polymorphism has no eﬀects on CVD
incidence [93]. The expression proﬁle of a soluble LOX-
1 species was elevated in obese postmenopausal women
[94], and it is a biomarker for type 2 diabetes mellitus and
atherogenesis [95–97]. In dendritic cells, LOX-1 can act as
a receptor that mediates the uptake of antigens [98]. Over-
expression of LOX-1 in CHO cells led to bacterial binding
anduptake[99].MacrophageLOX-1depletion inhibits foam
cell formation suggesting a role in atherosclerotic plaque
initiation and progression [100]. Importantly, the incidence
of atherosclerotic plaques is signiﬁcantly lowered in LOX-1-
deﬁcient mice [101].
Class F consists of the SREC gene products (scavenger
receptors expressed by endothelial cells) which are expressed
on mammalian endothelial cells and macrophages [102]a n d
also in nematodes [103]. The SREC-I gene is related to
the EGF precursor gene [104] and is located on human
chromosome 17 but the murine orthologue called SCARF-1
is located on mouse chromosome 11. In humans, alternative
splicing gives rise to at least ﬁve diﬀerent membrane-
bound and soluble protein isoforms [105]. SREC-I levels
are elevated by lipopolysaccharides [102] and repressed by
cytokinessuchasIL-1α,IL -1β,andTNF -α[105].Inhumans,
another gene called SREC-II that displays ∼35% similarity
to SREC-I i sl o c a t e do nc h r o m o s o m e2 2[ 104, 106]. Murine
SREC-II is located on chromosome 16 [107]. In C. elegans,
a SREC-like gene product called CED-1 is implicated in the
engulfment of apoptotic cells during animal development
and immune defense against pathogens [35, 108, 109].
SREC-I is a receptor for Ac-LDL [102].
The chemokine ligand CXCL16 is a class G scavenger
receptorthatbindsphosphatidylserine andoxidized lipopro-
tein (SR-PSOX). SR-PSOX is located on human chromo-
some 17 and mouse chromosome 11. SR-PSOX is highly
expressed on macrophages, smooth muscle cells, dendritic
cells, kidney and B cells with lower levels detected on the
endothelium, and T cells [110–119]. Monocyte SR-PSOX
expression is increased by TNF-α,I F N - γ,L P S ,o rO x L D L
stimulation [113, 115, 120]. In addition to SR-PSOX links to
atherosclerosis[120,121]wherethemoleculewasinducedin
vitro and in vivo by atherosclerosis-promoting inﬂammatory
signals [122], it is also involved in acute and adaptive
experimentalautoimmuneencephalomyelitis[123],CD8+T
cell recruitment during inﬂammatory valvular heart disease
[124], and bacterial phagocytosis [116]. A soluble form of
SR-PSOX functions as an activated T cell and NK cell-
recruiting chemokine [112, 125] and is a biomarker for acute
coronary syndrome [126].
ClassHscavengerreceptorsconsistofFasciclin,EGF-like,
lamin type EGF-like and link domain-containing scavenger
receptor-1 (FEEL-1), also known as stabilin-1 or CLEVER-1
[127]andFEEL-2(stabilin-2)aparalogousproteinwith39%
sequence identity to FEEL-1 [128–130]. The FEEL-1 gene
(STAB1) is located on human chromosome 3 and mouse
chromosome 14, and the FEEL-2 gene (STAB2)i sl o c a t e d
on human chromosome 12 and murine chromosome 10.
Expression levels of both FEEL-1 and -2 are high in the
liver and lymph nodes. FEEL-1 is expressed on monocytes,
macrophages, and endothelial cells whereas FEEL-2 expres-
sion was not detected on these cell types in humans [128].
FEEL-2 was found to be expressed in sinusoidal endothelial
cells in the liver, lymph node, spleen, and bone marrow
in mice as well as heart valve mesenchyme, brain, eyes,
and kidneys [131], with expression levels being increased
during development in the zebraﬁsh Danio rerio [132].
FEEL-1 is known to undergo alternate splicing to yield an
isoform lacking exon 27 [130]. Sorting nexin 17 (SNX17)
is required for maximum cell surface expression of FEEL-1
[133]. Knockdown of SNX17 leads to a dramatic reduction
incellsurfaceexpression,duetoincreaseddegradationofthe
receptor.
3. Scavenger Receptor Structureand Function
Scavenger receptors are present on diﬀerent tissues ranging
between macrophages, monocytes, platelets, endothelial,
smooth muscle, and epithelial cells. In addition to vascular
tissues, they are also detected in adipose and steroidogenic
tissues (Table 1)[ 9, 13, 82, 110, 134–137]. A general mecha-
nism underlying scavenger receptor levels is the elevation of
gene expression in response to ligand binding to cell surface
receptors, thus generating a positive feedback loop that
mediates enhanced ligand clearance and/or accumulation
[138, 139]. This is in contrast to other membrane-bound
receptors such as the low-density lipoprotein receptor (LDL-
R) that is downregulated in response to binding LDL ligand,
thus exhibiting a negative feedback mechanism [140].
Scavengerreceptorsaregenerallyclassiﬁedasmembrane-
bound proteins that bind modiﬁed LDL particles and
other polyanionic ligands. These include AcLDL, OxLDL,
Gram-positive and Gram-negative bacteria, apoptotic cells,
β-amyloid ﬁbrils, and advanced glycation end products
(AGE) (Table 1)[ 4, 5]. Following ligand binding, scavenger
receptors can mediate intracellular signaling and/or ligand
internalization. A generic model for such regulation is
o u t l i n e di nF i g u r e1. Although there is little structural
homology between the ligand-binding domains of scavenger
receptors from diﬀerent classes, mutagenesis studies have
revealed some conserved characteristics. These include pos-
itively charged arginine or lysine clusters in the ligand-
binding domain of either the LOX-1 scavenger receptor
[141]o rC D 3 6[ 142], respectively. Such amino acid clusters
appear to be required to mediate electrostatic interactions
with the predominantly negatively charged modiﬁed lipid
particle or polyanionic ligand although other noncharged
hydrophilic residues may also be involved [141]. The avidity
of ligand binding is also enhanced through the formation of
scavenger receptor dimers [143], trimers [144], and higher-
order oligomers [145].4 International Journal of Hypertension
Table 1: The major scavenger receptor ligands and expression proﬁles.
Class Scavenger
receptor Ligands Expression proﬁle Involvement in CVD?
AS R - A
AcLDL, OxLDL, β-amyloid,
molecular chaperones, ECM, AGE,
apoptotic cells, activated B-cell,
bacteria
Macrophages, mast, dendritic,
endothelial and smooth muscle cells
Yes—involved in OxLDL uptake by
macrophages leading to foam cell
formation
AM A R C O AcLDL, OxLDL, apoptotic cells, B
cells, bacteria Macrophages, dendritic cells No
B SR-B HDL, LDL, OxLDL, apoptotic cells Monocytes/macrophages,
hepatocytes and adipocytes
Reduces atherosclerosis through
reverse cholesterol transport of
HDL
BC D 3 6 AcLDL, OxLDL, HDL, LDL, VLDL,
β-amyloid, AGE, apoptotic cells
Macrophages, platelets, adipocytes,
epithelial and endothelial cells
Yes—OxLDL uptake into




ECM, AGE, apoptotic cells,
activated platelets, bacteria
Endothelial and smooth muscle
cells, macrophages, and platelets
Yes—OxLDL uptake in endothelial
cells, leads to endothelial
dysfunction
F SRECI/II AcLDL, OxLDL, molecular
chaperones, apoptotic cells Endothelial cells and macrophages Low levels of AcLDL uptake
G SR-PSOX OxLDL and bacteria
Macrophages, smooth muscle,
dendritic, endothelial cells, and B-
and T cells.
Yes—involved in OxLDL uptake in
macrophages
H FEEL-I/II AcLDL, molecular chaperones,
ECM, AGE, bacteria
Monocytes/macrophages,
endothelial cell No known link
SR-A: scavenger receptor class A, AcLDL: acetylated low density lipoprotein, OxLDL: oxidised low density lipoprotein, ECM: extracellular matrix, AGE:
advanced glycation end products, MARCO: macrophage receptor with collagenous structure, HDL: high density lipoprotein, LDL: low density lipoprotein,
VLDL: very low density lipoprotein, LOX-1: lectin-like oxidized low density lipoprotein receptor-1, FEEL-I/II: fasciclin, epidermal growth factor (EGF)-like,





















Figure 1: A generic model for scavenger receptor-mediated ligand binding, internalization, and signal cascade activation. Scavenger receptors
bind negatively charged ligands through clusters of conserved positively charged residues. Ligands are internalized by scavenger receptors
using a range of diﬀerent clathrin-dependent and independent pathways. Ligands can be degraded or accumulate. Ligand binding can
activate signaling cascades leading to diverse cellular functions including lipid peroxidation, apoptosis, endothelial cell dysfunction, and
monocyte attachment and diﬀerentiation leading to foam cell formation.International Journal of Hypertension 5
Scavenger receptor-ligand complexes can undergo
receptor-mediated endocytosis, traﬃcking through the
endosome-lysosome system leading to degradation
or accumulation of ligand. Diﬀerent mechanisms of
endocytosis have been postulated for the individual classes
of scavenger receptors including clathrin-dependent [146],
clathrin-independent [147], and lipid raft-mediated [148]
events. This diversity in scavenger receptor endocytosis
is not surprising considering the sequence diversity and
diﬀerent endocytic motifs within the cytoplasmic domains
of the diﬀerent scavenger receptors [146, 147]. Following
endocytosis and delivery to endosomes, it is likely that
many scavenger receptors are recycled back to the plasma
membrane where they can mediate further ligand binding,
clearance, or accumulation.
Ligand binding to scavenger receptors activates intra-
cellular signaling cascades leading to diverse physiological
outputs including apoptosis, endothelial cell dysfunction,
andlipidperoxidation.Oneaspectofscavengerreceptoracti-
vation is monocyte inﬁltration and diﬀerentiation leading to
foamcellformation,akeyeventinatheroscleroticplaqueini-
tiation and progression. For example, activation of the Class
B CD36 scavenger receptor is linked to phosphorylation and
activation of c-Src and MAP kinase pathway thus triggering
macrophage diﬀerentiation into foam cells [149]. Another
model is the LOX-1 scavenger receptor where ligand binding
stimulates reactive oxygen species (ROS) production, both
MAPK and NF-κB activation leading to increased expression
ofdiﬀerentadhesiongeneproducts.Suchelevatedexpression
in endothelium can enable monocyte inﬁltration, ultimately
leadingtomonocytediﬀerentiation andfoamcellformation.
4. Current Atherosclerosis Therapies
Atherosclerosis is a leading cause of mortality in Europe and
Western countries [150]. The subversion of human vascular
function by atherosclerosis can lead to cardiovascular
morbidityandmortality,includingischemicstroke,ischemic
heart disease, myocardial infarction, and peripheral arterial
disease. The causes of atherosclerosis are multifactorial,
meaning that single intervention therapy has as yet not
succeeded in major reductions in disease incidence.
Ongoing large investments by many countries worldwide
are directed towards the prevention of cardiovascular
disease by modifying environmental risk factors. Within
the United Kingdom alone, a vascular risk and assessment
program is currently in its initial roll out phase, aiming to
tackle modiﬁable risk factors in a healthy 40–74-year age
group (http://www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH 083822).
Despite economic modeling predicting a relatively
large annual cost (US$60 million), this approach is
predicted to prevent approximately 9500 cases of
myocardial infraction and strokes annually. This would
thus also be cost eﬀective in the long term. (http://
www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH 085869).
Pharmacological agents have only been partially
successful in attenuating the clinical manifestations of
atherosclerosis with the most dramatic eﬀects achieved by
statins, which inhibit 3-hydroxy-3-methyl glutaryl coenzyme
A (HMG-CoA) reductase. Statin therapy has reduced
the 5-year incidence of major cardiovascular events by
∼20% with each millimole per liter reduction in levels of
cholesterol in LDL particles [151]. It is thought that statins
exert their eﬀect through inhibiting the rate-limiting step
in cholesterol biosynthesis, which in turn leads to elevation
of LDL receptor expression. However there is much debate
over the importance of additional lipid-independent modes
of action including anti-inﬂammatory eﬀects [152]. Clinical
treatment of established atherosclerotic plaques is becoming
more technologically advanced, with routine intra-arterial
catheterization and angioplasty of damaged arterial blood
vessels. Stents are commonly used, and new technologies,
such as drug-eluting stents, raise exciting possibilities for
potential gene therapy as well. Evaluation of a patient’s
genetic background in atherosclerotic plaque initiation and
progression could be essential to provide major disease
alleviation by combining intervention, medication, and
lifestyle modiﬁcation in tailored therapies. Targeting the
scavenger receptor gene products that mediate the response
to and/or uptake of modiﬁed LDL holds great promise in the
prevention of cardiovascular disease.
5. Gene Therapy
Gene therapy is the process of ameliorating or curing a
genetic disease by introducing a fragment of genetic material
into diseased or dysfunctional cells. Viral or nonviral vectors
are the vehicles used to transfer and express speciﬁc genes
within a target cell and thus used to correct genetic
disorders. The idea of using genetic material to treat human
diseases gained prominence in 1960s [153], and in 1973,
the ﬁrst attempt used a wild-type human papilloma virus in
attempting to correct hyperargininaemia [154] but this was
unsuccessful.Eventhoughsubsequentgenetherapyattempts
were controversial [155], this area of biomedicine obtained
the ﬁrst signs of success by tackling adenosine deaminase-
deﬁcient severe combined immunodeﬁciency (ADA-SCID)
[156]. The ﬁrst ADA-SCID patient treated successfully using
this technology has subsequently led a relatively normal
lifestyle with amelioration of the disease symptoms [157].
By 2007, >1300 gene therapy clinical trials have taken
place of which the majority of trials (67%) aimed at
cancer treatment; gene therapy of cardiovascular diseases
formed the second largest cohort of clinical trials (9%). The
number of clinical gene therapy trials currently exceeds 1500
(http://www.wiley.co.uk/genmed/clinical/)a n dm a yw e l ll i v e
up to the expectations of becoming the “twenty-ﬁrst century
medicine” to deliver personalized healthcare [158].
Nevertheless, successful clinical gene therapy has
encountered numerous problems. The two major problems
that usually hamper gene therapy eﬃcacy are (1) immune
response(s) against the protein products of the transgene
or the vector and (2) insertional mutagenesis by the viral
vector. Since viral vectors are based on pathogenic viruses,
they can induce immune responses [159–161], and much
of the human population may have preexisting immunity6 International Journal of Hypertension
against human viruses. Depending on the conditions used,
this immunogenicity can lead to adverse eﬀects. During
one study on adenoviral-mediated treatment of ornithine
transcarbamylase (OTC) deﬁciency, one of the eighteen
subjects died as a result of an exacerbated immune response
to the injected adenoviral vector carrying an E1-E14 deletion
[162, 163]. Leukemia induction was also noticed in a mouse
model following gene transfer using retroviral vectors caused
by vector integration into the ecotropic viral integration
Site-1 (Evi1)[ 164]. Two diﬀerent gene therapy studies on
X-linkedSCID(SCID-X1)usingretroviralvectorintegration
resulted in leukemia induction in four out of nine subjects
with one death [165, 166] and leukemia in one out of ten
subjects [167, 168]. Retroviruses and lentiviruses undergo
obligatory integration of the provirus into the host genome
as a part of the life cycle, and this may lead to activation or
increased expression of nearby host genes [169, 170]. In the
case of retro- and lentiviral vectors, the promoter enhancer
elements located in the viral termini appear responsible for
this altered host gene expression proﬁle [171, 172].
In contrast, although the viral termini located within
adeno-associated viruses [173, 174] and adenoviruses [175–
177] have enhancer and promoter activities, insertional
mutagenesis caused by vectors based on these viruses have
not as yet been reported. However, even in the case of ade-
noviral vectors which have been perceived as nonintegrating
vectors, there are instances of viral integration into the chro-
mosomal DNA close to or within host genes and instances
of genetic mutations and rearrangements [178, 179]. A
slightly higher percentage of adeno-associated viral vector
DNA [180, 181] integrated into genes causing chromosomal
deletions and translocation [182–184]. Despite the lack of
adverse aﬀects in cystic ﬁbrosis gene therapy trials, the eﬀects
caused by administration of diﬀerent viral and nonviral gene
therapy vectors were not suﬃcient to cause regression of
clinical symptoms; natural lung adaptation to alien particle
administration may have also hindered patient gene transfer
[185]. However, successful gene therapy in the treatment
of ADA-SCID and lack of adverse eﬀects [186]h o l d sm u c h
promise for further work.
6. GeneTherapy Vectors
Gene therapy vectors are genetic vehicles used to transfer
DNA sequences or speciﬁc genes from the laboratory
bench into the diseased cells or tissues and are viral or
nonviral in origin. Viruses are well adapted to infect cells
or tissues, and these adaptations have been utilized to
generate viral vectors for gene therapy. Such viral vectors
constitute 66% of clinical gene therapy trials worldwide
(http://www.wiley.co.uk/genmed/clinical/). Both viral and
nonviral vectors have their advantages and disadvantages in
gene therapy (summarized in Table 2).
6.1. Nonviral Gene Therapy Vectors. Nonviral gene delivery
systems utilize physical force or chemical methods to deliver
the genetic material to the cell. Major nonviral vectors
used in gene therapy include circular plasmid or linear
DNA complexed with nanoparticles [187, 188]o rl i p o s o m e s
(cationic lipid-DNA complex) [189, 190]. Plasmid DNA
can be transferred into the cells using a gene gun [191]
where the DNA is bound to high density particles like gold
and transferred at high velocities into the cell [192]o rb y
electroporation [193], using transposable elements [194]
or DNA:RNA oligonucleotide hybrids [195]. Even though
nonviral gene therapy methods are used in clinical trials
[196] they usually exhibit lower gene transfer eﬃciency
and transient gene expression [197–200]. This is especially
true when both viral and nonviral systems were compared
simultaneously [201]; the immune response [202–205]m a y
also limit the therapeutic capability of nonviral gene therapy.
6.2. Viral Gene Therapy Vectors. Since viruses are well
adapted to evade the host immune responses and to deliver
the genetic material into the host cells, gene therapy vectors
based on viruses have been more eﬀective so far and
currently account for two-thirds of all gene therapy clinical
trials worldwide (http://www.wiley.co.uk/genmed/clinical/).
Barring the use of vectors in suicide gene therapy [206],
viral gene delivery systems utilize viral vectors with defective
replication capabilities. The coding region of the viral
genome is replaced by foreign genetic material, leaving only
the cis-acting elements essential for viral packaging and/or
integrating into the host genome on the vector. Producer
cell lines can provide the essential viral gene products either
totally by themselves or by the assistance of other systems,
which are used to generate nonreplicating viral vectors
[207]. Currently, vectors based on adeno-associated viruses,
retroviruses, and adenoviruses form the majority of the viral
v e c t o r su s e da sg e n ed e l i v e r ys y s t e m s .
6.2.1. Adeno-Associated Viral (AAV) Vectors. Adeno-
associated viruses belong to the Parvoviridae family which
have a nonenveloped icosahedral capsid containing a
single-stranded DNA genome. This viral DNA has cis-acting
palindromic inverted terminal repeats at each end which
form hairpins that are essential for DNA replication and
packaging [208]. Most of the current AAV-based gene
therapy vectors are derived from AAV-2 subtype. This virus
is dependent on coexpression of an adenovirus or herpes
helper virus for gene products essential for lytic productive
infection where the genome is replicated, and virions
are produced. In the absence of the helper virus, AAV-2
undergoes site-speciﬁc integration to establish a latent state.
The provision in trans of the AAV Rep (regulatory) and Cap
(structural capsid) genes together with the adenoviral early
viral genes (provided by a helper virus) is needed to generate
AAV vectors for gene therapy [158, 207, 209]. Despite the
smaller AAV transgene capacity [210] and the preexisting
immunity against AAV [211], these vectors have been used
successfully in animal models of retinal disorders [212, 213],
cystic ﬁbrosis [214, 215], hemophilia B [216, 217], muscular
dystrophy, and DNA vaccination [218]. They are currently
used in human clinical gene therapy trials [219].
6.2.2. Adenoviral Vectors. Adenoviruses belong to the Aden-
oviridae familyandcontainnonenvelopedicosahedralcapsid
with a double-stranded DNA genome. A cis-acting invertedInternational Journal of Hypertension 7
terminal repeat is present at each end of the DNA and
a packaging signal at the 5  terminus [220]. Some of
the early adenoviral genes (e.g., E1) have transforming
and transactivating functions and were thus replaced by
inserted DNA sequences or the gene of interest in the ﬁrst
generation adenoviral vectors. However, this did not prevent
low level expression of other adenoviral gene products,
including those with immunogenic and toxic properties
causing rapid clearance from host in vivo [221, 222]. To
both avoid this adaptive immune response and to increase
viral transgene capacity, high capacity adenoviral vectors
(HC-AdV) were developed where the only viral elements
present are the cis-acting ITRs and packaging signal with
viral gene products needed for replication provided in
trans by a packaging-deﬁcient helper virus [223]. Even
though the innate immunity against adenoviral capsid
would still elicit an immune response [161], this may
be circumnavigated either by using adenoviral vectors of
diﬀerent serotypes [224] or by modiﬁcations with synthetic
polymers [225]. The large cloning capacity of 36kb and
the longevity of transgene expression [226–228]i nt i s s u e s
with low cellular turnover hint at potentially successful
gene therapy. Adenoviral vectors have been used successfully
in rodent, canine, and primate models of cardiovascular
diseases [229, 230], muscular dystrophy [231, 232], glycogen
storage diseases [233], hemophilia [234], cancer [235–237],
retinal disorders [238], and DNA vaccination studies [239].
Adenoviral vectors comprise the largest group of the largest
group of vectors (24%) used in clinical gene therapy trials
(http://www.wiley.co.uk/genmed/clinical/)[ 240, 241].
6.2.3. Retro- and Lentiviral Vectors. Retroviruses are envel-
oped single-stranded RNA viruses where the RNA genome
is reverse transcribed into a DNA provirus which then inte-
grates into the host chromosomal DNA during its life cycle.
The viral genome is ﬂanked by long terminal repeats (LTRs)
which along with the packaging signal and a truncated
gag gene comprising the cis-acting elements essential for
functionality. Retroviral genes encoding the capsid proteins,
the viral protease, the reverse transcriptase, and the integrase
are supplied in trans by transient transfection of plasmids
to generate an assembled virus with gene delivery capability
[242–244]. Lentiviruses are more complex, regulatory and
accessory genes, and have the capability to infect dividing
and nondividing cells in contrast to retroviruses which can
only infect dividing cells. Functional lentiviral vectors also
need expression of the Rev (cytoplasmic transport of the
RNA) and the Tat (viral promoter transactivator) viral gene
products.
One biosaftey issue when using viral gene therapy
is that extensive genetic recombination of the viral and
host genomes could generate replication-competent viruses.
Whilstthegenerationofreplication-competentadenoviruses
may cause only relatively mild health problems, this is likely
to be dangerous if replication-competent lentiviruses are
generated.Toreducethisriskduringthepackagingprocessin
vitrousingculturedcelllines,gag andpol (withadditionaltat
andrev forlentiviralvectors)andenv arepresent on diﬀerent
plasmids. A further biosafety improvement is removal of
the U3 region (enhancer-promoter) of the viral LTR to
generate self-inactivating (SIN) vectors [245]. Since reverse
transcription meansthat both the5  and 3  U3 regions of the
provirus DNA are transcribed, this deletion would abrogate
synthesis of a complete RNA viral genome packaged into
virions. One feature of the retrovirus life cycle is integration
of the provirus into the host genome causing persistent gene
expression [246]. Gene therapy using retro- or lentiviral
vectors has been successfully used in the gene therapy
experiments for treating Duchenne muscular dystrophy
[247], hemophilia [248], Fanconi anemia [249], diseases of
the central nervous system [250], DNA vaccination [251],
X-linked SCID, adenosine deaminase SCID, and chronic
granulomatous disease [168, 252]. These successes of these
studies in a combination of rodent, canine, primate models
have now led to ∼21% of current human clinical trials for
gene therapy.
7. Scavenger Receptor GeneTherapy
Even in the late 1980s, cardiovascular dysfunction was a
major focus of gene therapy trials. In a rabbit model of
homozygous familial hypercholesterolemia, a retroviral LTR
promoter was used to overexpress human LDL-R in ﬁbrob-
lasts [253]. Elsewhere, retroviral vectors containing LacZ
encoding β-galactosidase were used for ex vivo transduction
of canine and porcine endothelial cells: β-galactosidase
expression could be detected after surgical implantation
into canine and porcine models [254, 255]. Currently, the
proportion of clinical gene therapy trials for cancer (65%) is
followed by the second largest trial group on cardiovascular
disease (9%) (http://www.wiley.co.uk/genmed/clinical/).
Asmentionedearlier,scavengerreceptorfunctionisasso-
ciated with both healthy and pathophysiological processes
ranging between homeostasis, apoptotic cell clearance, dia-
betic necropathy, age-induced cardiomyopathy, and antigen
cross-presentation in Alzheimer’s disease [256–260]. Impor-
tantly scavenger receptor function is heavily implicated
in atherosclerotic plaque initiation and progression [261],
making this diverse protein supergroup [1] an attractive
target for gene therapy (Figure 3). Currently, the majority
of scavenger receptor gene therapy studies have utilized
adenoviral vectors (Table 3).
7.1. LOX-1 Gene Therapy. A mouse knockout model lacking
LOX-1 suggested that this was a key contributory factor in
driving lipid accumulation in vascular tissues [101], raising
thequestionastowhetherthesepropertiescouldbemanipu-
latedusinggenetherapy.Aﬁrst-generationadenoviralvector
expressing human LOX-1 was used to successfully express
LOX-1 transiently in vascular smooth muscle cells (VSMCs)
and other cells [262]. A ﬁrst-generation ﬁrst-generation
adenoviral vector was used to provide ectopic expression of
LOX-1 in hepatic tissues of the ApoE-deﬁcient mice, leading
to increased OxLDL excretion, reduction in plasma OxLDL,
and complete loss of atherosclerotic plaque initiation and
progression [263]. In addition, oxidative stress and inﬂam-
matory responses were reduced in the mice infected with
adenovirus LOX-1. Nevertheless, OxLDL levels returned to8 International Journal of Hypertension
Table 2: The advantages and disadvantages of the major gene therapy vectors currently used.
Gene therapy
vector Genetic material Advantages Disadvantages
Nonviral vectors Mainly DNA Large transgene capacity, biosafety Low eﬃciency, immune response (cationic
lipids and polymers), toxicity
Retro-/lentiviral
vectors RNA Stable integration, lack of immune response,






DNA Long-term expression, site-speciﬁc




DNA High titer, up to 8kb of cloning capacity
Immune response and toxicity leading to





DNA High titer, longevity of transgene
expression, up to 36kb cloning capacity
Immune response directed against the viral
capsid
control baseline levels 3 weeks after hepatic LOX-1 over-
expression. This proﬁle of gene expression correlates with
the expected duration of transgene expression using ﬁrst
generation adenoviral vectors [221]. This raises the question
whether more sustained long-term LOX-1 expression using
stable ectopic expression systems or integrating viruses
would be a better strategy to inhibit atherosclerosis.
7.2. SR-A Gene Therapy. A retroviral vector with a bovine
SR-AII cDNA transgene was used to show increased lipid
accumulation, foam cell formation, and predisposition to
apoptosis in ﬁbroblasts and smooth muscle cell lines [264].
This suggests that manipulation of SR-A levels might
be advantageous in hindering proatherogenic responses
in vascular tissues [264]. A hybrid gene containing the
humanCD68promoterupstreamoftruncatedhumanSR-AI
encoding the extracellular domain alone and expressed using
an adenoviral vector inhibited degradation of AcLDL and
OxLDL particles and subsequent foam cell formation [265].
One conclusion is that soluble SR-AI binds to modiﬁed LDL
particlesandsequesterssuchligandsawayfromthewild-type
membrane-bound scavenger receptors.
Using the LDL-R knockout mouse that develops
atherosclerotic lesions, overexpression of soluble human
SR-AI using this adenoviral system completely blocked
plaque initiation and progression [266]. However, similar
to gene expression proﬁles for ﬁrst- and second-generation
adenoviral vectors, the plasma soluble SR-AI returned to
control baseline levels after 4 weeks [266]. When adeno-
associated viral vectors were used to express soluble SR-AI
in the same mouse model, the atherosclerotic lesion area was
reduced and persistence of soluble SR-AI plasma levels was
observed for 6 months [267]. Expression of murine MARCO
using a lentiviral vector in cultured cells suggests that quality
control along the secretory pathway is essential for scavenger
receptor assembly and presentation at the plasma membrane
[274]. SR-A may also be a receptor for adenovirus binding
and host cell entry [275], and this could be further exploited
to block macrophage lipid accumulation leading to foam cell
formation during atherosclerosis.
7.3. SR-BI Gene Therapy. High-density lipoprotein (HDL)
particles can mediate reverse cholesterol transport, have
antiatherogenic properties, and are recognized by the SR-
BI glycoprotein [276, 277]. Current gene therapy used
ﬁrst-generation adenoviral vectors to express murine SR-
BI. Transient hepatic expression of murine SR-BI in mice
increased HDL clearance, reduction in plasma HDL levels,
and increased biliary cholesterol levels [54]. These eﬀects are
either due to increased hepatic uptake of HDL and/or the
increased cholesterol secretion into the bile. Similar results
were obtained with the same adenoviral vector delivered
into LDL-R knockout mice with reduction of both early
andadvancedatheroscleroticlesions[55].Oneexplanationis
that SR-BI overexpression resulted in a reduction of all three
of HDL, LDL, and VLDL levels [278]. However, in human
ApoB transgenic mice, SR-BI expression from the same
vector resulted in a much lesser LDL-metabolism compared
to HDL metabolism [279]. A xenogenic model comprising
ApoAI knockout mice and SR-BI overexpression was used to
examine transplanted human HDL processing. Here, small
and dense HDL particles are not cleared from the circulation
but remodel in the plasma to form larger HDL particles
[280]. Similar SR-BI expression in a rabbit model caused
reduction in HDL levels and increased LDL levels [268].
Again, SR-BI overexpression increased biliary excretion of
cholesterol [269].
HDL binding to SR-BI can activate intracellular signaling
leadingtoincreasedendothelialnitricoxidesynthase(eNOS)
activity[281].CoexpressionofSR-BIandApobec1(essential
in ApoB mRNA editing, resulting in the truncated ApoB48
product) in immortalized hepatic cells using a HC-Ad
vector caused reduction in ApoB levels. Using the same
system on immortalized endothelial cells caused increased
eNOSphosphorylationandelevatednitricoxidelevels[270].
However, the amount of HDL normally absorbed by the
liver from the bloodstream is relatively low [282]. SR-BI
allelicpolymorphismsalsodonotcorrelatewithvariationsin
plasma HDL levels [283]. More clinical gene therapy studies
are desirable to fully test whether this molecule is a good
candidate for alleviating atherosclerosis.International Journal of Hypertension 9
Table 3: List of the main viral gene therapy experiments examining the therapeutic potential of scavenger receptors.
SR
used/targeted Vector used Outcome References
LOX-1 FG AdV Inhibition of the progression of
atherosclerosis Ishigaki et al. [263]
Soluble SR-A1 FG AdV Foam cell formation inhibited Laukkanen et al. [265]
Soluble SR-A1 FG AdV Abrogation of the atherosclerotic lesion area Jalkanen et al. [266]
Soluble SR-A1 AAV Abrogation of the atherosclerotic lesion area Jalkanen et al. [267]
SR-B1 FG AdV Reduction of plasma HDL Kozarsky et al. [54]
SR-B1 FG AdV Reduction of plasma HDL Kozarsky et al. [55]
SR-B1 FG AdV Reduction of plasma HDL, increase of LDL Tancevski et al. [268]
SR-B1 FG AdV Increased biliary secretion of cholesterol Wiersma et al. [269]
SR-B1 and
Apobec 1 HC-AdV Reduction of Apo B levels, elevation of NO Zhong et al. [270]
SR-B1/CD36 FG AdV
SR-B1 mediated uptake of cholesterol esters
higher than that by CD36. However, CD36
resulted in higher levels of Ox-LDL
degradation
de Villiers et al. [271] and Sun et al. [272]
CD36 FG AdV Increased hepatic fatty acid uptake Koonen et al. [273]
SR-PSOX LV Decreased foam cell formation Zhang et al. [120]
SR: scavenger receptor, FG AdV: ﬁrst-generation adenoviral vector, AAV: adeno-associated viral vector, HC-AdV: high capacity adenoviral vector, LV: lentiviral
vector, SR-A: scavenger receptor class A, LOX-1: lectin-like oxidised low density lipoprotein receptor-1, SR-B1: scavenger receptor class B 1, SR-PSOX:
scavenger receptor that binds to phosphatidylserine and oxidized lipoprotein, Apobec 1: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like




























delivery of transgene, or
by gene blockade (e.g.,
decoy oligonucleotides,
siRNA)
Figure 2: Treatment of atherosclerosis. A schematic to display the potential synergistic role of gene therapy in the treatment of atherosclerosis.
7.4. CD36 Gene Therapy. CD36 is another Class B scav-
enger receptor that can mediate oxidized LDL binding and
internalization [284]. Liver overexpression of CD36 using
a ﬁrst-generation adenoviral vector signiﬁcantly increased
cellularfattyaciduptakeincludinghepaticfattyacid,plasma,
and hepatic triglycerides [273]. Constitutive expression of
murine SR-BI or the murine CD36 using a ﬁrst-generation
adenoviral vector in cultured cells in vitro showed that
SR-BI-mediated uptake of cholesterol esters was higher
than CD36 [271]. Hepatic SR-BI overexpression signiﬁcantly
reduced HDL levels whereas CD36 overexpression had little
eﬀect [271]. However, in another study using the same in
vitromodel, CD36-mediated OxLDLinternalization resulted
in signiﬁcantly higher lipid particle degradation, compared
to SR-BI [272]. These ﬁndings suggest signiﬁcant diﬀerences



























Figure 3: Major scavenger receptors and their eﬀects on atherosclerosis. A schematic showing the role of major scavenger receptors in
atherosclerosis. Red arrows indicate proatherogenic eﬀects; green arrows indicate antiatherogenic or protective eﬀects. SR-A (scavenger
receptor class A) mediates uptake of OxLDL (oxidised low density lipoprotein) in macrophages; SCARA5 (scavenger receptor A5) down-
regulation results in reduction of aortic LDL (low density lipoprotein) deposition; CD36 is probably a receptor of OxLDL; SR-B (scavenger
receptor B) increases cholesterol eﬄux; CD163 exerts its protective actions through elevation of IL-10 and heme oxygenase; CD68 is a
possible receptor for OxLDL; LOX-1 is a receptor for OxLDL; SREC-1 (scavenger receptors expressed by endothelial cells) is a receptor for
AcLDL (acetylated low density lipoprotein); SR-PSOX (scavenger receptor that binds to phosphatidylserine and oxidized lipoprotein) binds
to OxLDL (ﬁgure adapted from [1]).
CD36 overexpression may be more beneﬁcial by promoting
the clearance of modiﬁed lipid particles.
7.5. SR-PSOX Gene Therapy. The scavenger receptor that
binds to phosphatidylserine and oxidized lipoprotein (SR-
PSOX) is highly expressed within atherosclerotic lesions
[111], and elevated expression in macrophages stimulates
OxLDL uptake [285]. Reduction of human SR-PSOX levels
in immortalized monocytes by RNAi using a lentiviral vector
decreased lipid accumulation and foam cell development
[120]. However, in double knockout mice lacking both LDL-
R and SR-PSOX, there was accelerated atherosclerosis with
increased macrophage recruitment to the aortic arch [121].
The potential role of SR-PSOX in the innate immune system
to mediate pathogen clearance [125, 286] suggests that more
studies may be needed to ascertain potential beneﬁts of the
SR-PSOX manipulation in vivo.
8. Conclusions
Treatment of atherosclerosis using pharmacological agents
has only been partially successful, and therefore newer
therapies, either stand-alone ones or in combination
with the pharmacological agents, are desirable (Figure 2).
Gene therapy has been successful in human and animal
models with more than 1500 clinical trials worldwide
(http://www.wiley.co.uk/genetherapy/clinical/). Viral vectors
appear better than nonviral vectors to deliver transgenes to
target cells and tissues. Despite the setbacks to viral gene
therapy due to insertional mutagenesis caused by the viral
vectors or anti-viral host immune responses, better vectors
with signiﬁcant safety biosafety improvements have been
developed Self-inactivating lentiviral vectors [245]a r es a f e r ,
and modiﬁcations of the viral long terminal repeats further
reduce the potential of insertional mutagenesis by retro-
and lentiviral vectors [287]. Even though viral integrations
have been observed near transcription start sites and genes,
foamy viruses have reduced preferential integration into host
genes [288] in comparison to other viral systems [170, 179],
and thus this class of viruses may be signiﬁcantly safer than
retro- or lentiviruses when used as vectors. Most of the
adenoviral vectors currently being used are based on Ad5
serotype; however, since neutralizing host antibodies to the
Ad5serotypeexceedsthattotheAd36 serotypeinthehuman
population [289], Ad36-derived vectors may be better for
human clinical trials. Intrahepatic injection of adenoviral
vectors also help in reducing the immune response and
increasing transgene expression [290] .T h ep r o b l e m sa r i s i n g
from the preexisting host immune responses against Ad5
serotype can also be circumnavigated using vectors based on
a canine adenovirus [224]. Viral vectors can also be made to
speciﬁcally target the desired cell type [291–294], and this
strategy should help in improving the overall eﬃcacy of the
therapy.
Even though the ﬁrst successful clinical gene therapy
trial took place almost twenty years ago, work on its
utility for modulating scavenger receptor function is still in
its infancy (summarized in Table 3). Hepatic overexpres-
sion of scavenger receptors using viral vectors resulted in
the inhibition of atherosclerosis initiation and progressionInternational Journal of Hypertension 11
[263, 265, 266] even though therapy eﬃcacy was hampered
by lack of stable long-term gene expression. Better results
were obtained when a diﬀerent viral vector was used
[267]. A study of the long-term eﬀect of the transgene
expression in vivo using the other available viral vector
types would be very desirable to ascertain the potential of
usingviralgenetherapyusingscavengerreceptors.Thesplice
v a r i a n ti s o f o r m so fs o m es c a v e n g e rr e c e p t o r sc a nc o n f e r
protection against myocardial infarction [88], and it might
be interesting to examine expression of these molecules in
an in vivo model. The long-term eﬀects of the expression
of soluble scavenger receptors on atherosclerosis would be
interesting [265–267]. Since scavenger receptor knockout
models can be antiatherogenic [120], suppression of gene
expression appears to be a promising strategy although
eﬀects on the host immune responses have yet to be fully
understood. A dual approach where genetic manipulation of
a candidate scavenger receptor is supplemented by the action
of another transgene [270] combined with longer duration
of transgene expression might increase therapeutic beneﬁts
in disease models. Adeno-associated viral vectors may not
be very useful in the simultaneous expression of a number
of transgenes from a single vector due to the limitations
in their packaging capacity, but multiple transgenes can be
expressed in the model system with large vectors such as
HC-AdVs. Transgene expression from viral vectors such as
HC-Ad and lentiviruses is relatively stable and long-lived
but these vectors have been used sparingly for such studies
with scavenger receptors. With the advent of gene therapy
vectors with higher biosafety such as SIN-LV vectors and
HC-AdV vectors, development of less immunogenic viral
vectors based on nonhuman viruses [224], and suppression
of transgene-speciﬁc immune responses [295] gene therapy
with scavenger receptors along with other therapies might be
useful in providing sustained long-term amelioration of the
clinical manifestations of atherosclerosis.
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